AVRO Archives - BioTuesdays

Developments

AVROBIO to sell cystinosis gene therapy program for $87.5-million

AVROBIO (NASDAQ:AVRO) agreed to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5-million. Cystinosis is a rare, multisystem genetic...

May 22, 2023

Markets

SVB Leerink cuts AVROBIO PT to $10 from $18

SVB Leerink reduced its price target for AVROBIO (NASDAQ:AVRO) to $10 from $18 but maintained its “market perform” rating after the company announced that it may no longer pursue an accelerated approval pathway for AVR...

May 3, 2021

Markets

Stifel starts coverage on 10 rare disease-focused companies

Stifel began coverage on 10 rare disease-focused companies, with seven “buy” and three “hold” ratings, noting that with an estimated 7,000-plus rare diseases – 95% of which lack approved therapy – these are early...

March 1, 2021

Developments

AVROBIO updates data on gene therapy trials for Fabry disease, cystinosis

AVROBIO (NASDAQ:AVRO) updated data on its Phase 2 and Phase 1/2 trials evaluating its lentiviral-based gene therapies for the treatment of Fabry disease and cystinosis, respectively. Fabry disease is a genetic disease...

May 13, 2020

Developments

AVROBIO doses first patient in Phase 1/2 gene therapy trial for cystinosis

AVROBIO (NASDAQ:AVRO) dosed the first patient in its Phase 1/2 clinical trial of AVR-RD-04 gene therapy for the treatment of cystinosis. Caused by a mutation in the cystinosin gene, cystinosis is a lysosomal storage...

October 8, 2019

Developments

AVROBIO’s IND for commercial-scale Fabry disease gene therapy cleared by the FDA

AVROBIO’s (NASDAQ:AVRO) IND for AVR-RD-01 – a gene therapy candidate for the treatment of Fabry disease – has been cleared by the FDA, enabling AVROBIO to use its commercial-scale gene therapy manufacturing system...

April 30, 2019

Tag - AVRO

AVROBIO to sell cystinosis gene therapy program for $87.5-million

SVB Leerink cuts AVROBIO PT to $10 from $18

Stifel starts coverage on 10 rare disease-focused companies

AVROBIO updates data on gene therapy trials for Fabry disease, cystinosis

AVROBIO doses first patient in Phase 1/2 gene therapy trial for cystinosis

AVROBIO’s IND for commercial-scale Fabry disease gene therapy cleared by the FDA

General

More